Detecting Oligometastatic Breast Cancer with FDG PET-CT

Host Dr. Reni Butler sits down with outgoing Radiology Editor-in-Chief Dr. Linda Moy for an inspiring conversation about leadership, innovation, and the future of medical imaging. Dr. Moy reflects on her tenure at the journal, the impact of AI on radiology, and her vision for the next era of patient-centered care.  

Dr. Ashwin Singh Parihar speaks with Dr. Gary Ulaner about new research comparing FDG PET-CT and conventional imaging for detecting oligometastatic breast cancer. They explore how advanced imaging can improve staging accuracy, the challenges of detecting lobular cancer, and the evolving role of targeted therapies in this emerging field. 18F-FDG PET/CT of Oligometastatic Disease in LocallyAdvanced Breast Cancer: PETABC Trial Post Hoc Analysis. Metser et al. adiology 2025; 316(2):e243788. Detection of Oligometastatic Disease in Breast Cancer:It's the Little Things That Count. Ulaner. Radiology 2025; 316(2):e251797.    

Dr. Linda Chu speaks with Dr. Michael Trambert and Florent Saint-Clair about the unique workflow challenges in mammography and breast imaging. They explore clinical hurdles, the promise and pitfalls of AI, and how interoperability solutions can streamline efficiency and improve patient care. Sponsored by Dicom Systems. 

Dr. Linda Chiu unpacks how natural language processing and large language models are transforming radiology, with insights from a review by Dr. Felipe Kitamura and colleagues. From tokenization to transformers, she explores both the promise and challenges of applying these powerful AI tools to clinical practice. Texts Are More than Notes, They Are Data: A Glimpse intoHow Machines Understand Text. Kitamura et al. Radiology 2025; 316(2):e243217.

Dr. Refky Nicola speaks with Dr. Bari Dane, Associate Professor of Radiology at NYU, about the new SAR consensus recommendations for defining small bowel Crohn's disease strictures on CT and MR enterography. They explore updated imaging criteria, the challenges of distinguishing inflammation from fibrosis, and emerging roles for ultrasound and AI in diagnosis and treatment response. SAR Consensus Recommendations for Defining Small BowelCrohn Disease Strictures at CT and MR Enterography. Dane et al. Radiology 2025; 316(1):e243123.

Dr. Lauren Kim speaks with Dr. Anna Rita Larici about the international consensus guidelines for imaging and managing post-COVID-19 residual lung abnormalities. They discuss the importance of standardized definitions, CT imaging protocols, and unified terminology to guide diagnosis and follow-up care for patients with long COVID. Best Practice: International Multisociety Consensus Statement forPost–COVID-19 Residual Abnormalities on Chest CT Scans. Yoon et al. Radiology 2025; 316(1):e243374.

Dr. Linda Chu speaks with Dr. Andrew Trout, Professor of Radiology and Director of Clinical Research at Cincinnati Children's, and Dr. Erin Angel, Vice President of Research and Scientific Affairs at GE HealthCare. They discuss the unique challenges of pediatric imaging and how collaboration and technology are advancing care for young patients while improving imaging for all. Sponsored by GE HealthCare.

Dr. Linda Chu and Dr. Sid Dogra speak with Jessie Gommers and Dr. Ioannis Sechopoulos about their study on how AI decision support influences radiologist performance and visual search in screening mammography. They explore key findings on sensitivity, specificity, reading time, and the future role of visual tracking in optimizing human–AI collaboration. Influence of AI Decision Support on Radiologists' Performance and Visual Search in Screening Mammography. Gommers and Verboom et al. Radiology 2025; 316(1):e243688.  

Dr. Refky Nicola speaks with Dr. Perry Pickhardt about his study comparing CT colonography and multi-targeted stool DNA testing for colorectal cancer screening. They explore differences in sensitivity, specificity, cost-effectiveness, and strategies to optimize detection while minimizing invasiveness. CT Colonography versus Multitarget Stool DNA Test forColorectal Cancer Screening: A Cost-Effectiveness Analysis. Pickhardt et al. Radiology 2025; 315(3):e243775.

In this episode, we explore how nonprofit organizations like LBDA are working alongside industry partners to shape the evolving landscape of dementia biomarkers—bridging scientific innovation with real-world care. Featuring an engaging conversation with Dr. Sudhir Sivakumaran, Dr. Kathleen Poston, and Dr. Dustin Dunham on clinical utility, patient-centered research, and the road to broader adoption of biomarkers in Lewy body dementia, Alzheimer's disease and related disorders. This episode is sponsored by GE HealthCare